210687-07-3

Basic information

• Product Name: 3-O-benzyl laxogenin
• Synonyms: 3-O-benzyl laxogenin
• CAS NO: 210687-07-3
• Molecular Weight: 520.753
• Mol File: 210687-07-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-O-benzyl laxogenin(CAS DataBase Reference)
• NIST Chemistry Reference: 3-O-benzyl laxogenin(210687-07-3)
• EPA Substance Registry System: 3-O-benzyl laxogenin(210687-07-3)

Safety Data

• Hazardous Substances Data: 210687-07-3(Hazardous Substances Data)

Upstream product

• 146333-24-6 3-O-benzyl diosgenin 
• 100-39-0 benzyl bromide 
• 512-04-9 diosgenin 
• 210687-05-1 3β-O-benzylchlorogenin 

Downstream Products

• 210687-09-5 (25R)-3β-(benzyloxy)-5α-spirostan-6β-ol 
• 20470-24-0 (25R)-3β-hydroxy-5α-spirostan-6-one 
• 1383476-34-3 C₄₁H₅₄O₅ 
• 1383476-52-5 6-O-benzoyl-6β-chlorogenin 3-O-(3,6-di-O-benzoyl-β-D-glucopyranoside) 
• 1383476-51-4 laxogenin 3-O-(3,6-di-O-benzoyl-β-D-glucopyranoside) 
• 1383476-48-9 6-O-benzoyl-6β-chlorogenin 3-O-(3,6-di-O-benzoyl-2,4-di-O-levulinoyl-β-D-glucopyranoside) 
• 1383476-44-5 6-O-benzoyl-6β-chlorogenin 
• 210687-23-3 (3S,5S,6R,8R,9S,10R,13R,14S,15R,16R,17R)-3,6-Bis-benzyloxy-17-((1R,5R)-6-hydroxy-1,5-dimethyl-hexyl)-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthrene-15,16-diol 
• 210687-15-3 (3S,5S,6R,8R,9S,10R,13S,14S,17R)-3,6-Bis-benzyloxy-17-[(1R,5R)-6-(tert-butyl-dimethyl-silanyloxy)-1,5-dimethyl-hexyl]-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-16-one 
• 210687-13-1 (3S,5S,6R,8R,9S,10R,13S,14S,16S,17R)-3,6-Bis-benzyloxy-17-[(1R,5R)-6-(tert-butyl-dimethyl-silanyloxy)-1,5-dimethyl-hexyl]-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-16-ol 
• 210687-17-5 [(2R,6R)-6-((3S,5S,6R,8R,9S,10R,13R,14S,17S)-3,6-Bis-benzyloxy-10,13-dimethyl-2,3,4,5,6,7,8,9,10,11,12,13,14,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-methyl-heptyloxy]-tert-butyl-dimethyl-silane 
• 210687-21-1 (3S,5S,6R,8R,9S,10R,13S,14S,15R,17R)-3,6-Bis-benzyloxy-15-hydroxy-17-((1R,5R)-6-hydroxy-1,5-dimethyl-hexyl)-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-16-one 
• 210687-10-8 (25R)-3β,6β-bis(benzyloxy)-5α-spirostane 
• 210687-18-6 (2R,6R)-6-((3S,5S,6R,8R,9S,10R,13R,14S,17S)-3,6-Bis-benzyloxy-10,13-dimethyl-2,3,4,5,6,7,8,9,10,11,12,13,14,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-methyl-heptan-1-ol 

Relevant articles and documents

Structure-activity relationships of saponin derivatives: A series of entry inhibitors for highly pathogenic H5N1 influenza virus

The occurrence of highly pathogenic avian influenza virus H5N1 highlights the urgent need for new classes of antiviral drugs. Theoretically, each of steps in influenza viral life cycle can be a target of antiviral therapeutics. However, up to date, no licenced entry inhibitor drug is available for H5N1 or any other influenza viruses. Our strategy for developing new anti-influenza therapeutics is to target the interaction between HA and sialic acid which is influenza viral receptor presented on host cell surface. Here, based on our previously discovered small molecule inhibitor saponin 1, intensive SAR studies around the sugar chain and aglycone were conducted. The results showed that both the chacotriosyl residue and the chlorogenin moiety of active compound 1 are important for the antiviral activity, although several subtle modifications can be made on particular positions.

Synthesis of (25R)-5α-Cholestane-3β,6β,15α,16β,26-pentol, a Cytostatic Starfish Steroid1

The synthesis of (25R)-5αa-cholestane-3β,6β 15α,16β,26-pentol (1a), a marine cytostatic steroid, has been achieved in 13 steps (7.8% overall yield) starting from commercially available diosgenin (2). A key step in the synthesis was the dimethyldioxirane oxidation of the enolsilane 16 to introduce the 15α-hydroxy group in the D ring.